These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9409497)

  • 41. The past and future of haemophilia: diagnosis, treatments, and its complications.
    Peyvandi F; Garagiola I; Young G
    Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health care resource utilization and cost of care for haemophilia A and B patients in Iran.
    Gharibnaseri Z; Davari M; Cheraghali A; Eshghi P; Ravanbod R; Espandar R; Hantooshzadeh R
    Transfus Apher Sci; 2016 Feb; 54(1):122-6. PubMed ID: 26847868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in the management of haemophilia and christmas disease.
    Biggs R
    Clin Haematol; 1979 Feb; 8(1):95-114. PubMed ID: 367667
    [No Abstract]   [Full Text] [Related]  

  • 47. The haemophiliac in the eighties. Workshop II: Mobilizing support for haemophilia care.
    Haemostasis; 1981; 10 Suppl 1():51-79. PubMed ID: 6790371
    [No Abstract]   [Full Text] [Related]  

  • 48. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
    Gringeri A; Mantovani LG; Scalone L; Mannucci PM;
    Blood; 2003 Oct; 102(7):2358-63. PubMed ID: 12816859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Haemophilia treatment in 2030.
    Berntorp E
    Haemophilia; 2016 Jul; 22 Suppl 5():15-9. PubMed ID: 27405670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Healthcare resource utilization among haemophilia A patients in the United States.
    Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
    Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haemophilia care in South Africa: 2004-2007 look back.
    Mahlangu JN;
    Haemophilia; 2009 Jan; 15(1):135-41. PubMed ID: 18700842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.
    Mishra V; Tjønnfjord GE; Paus AC; Vaaler S
    Haemophilia; 2002 Nov; 8(6):809-14. PubMed ID: 12410652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changing pattern of care of boys with haemophilia in western European centres.
    Chambost H; Ljung R;
    Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
    Aledort LM; Cohen M; Hilgartner M; Lipton R
    Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
    [No Abstract]   [Full Text] [Related]  

  • 60. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.